Top 5 Safest Stocks To Buy For 2019

U.S. home prices are on a roll. And as we head into the New Year, I am expecting another record year for home prices in 2018. Today, I am going to reveal the safest, easiest and most profitable way to benefit from this trend.

Fueled by record-low interest rates and housing inventories, home prices in the United States hit another all-time high in 2017.

The S&P CoreLogic Case-Shiller 20-City Composite Home Price NSA (SPCS20) Index measures the value of residential real estate in 20 major U.S. metropolitan areas, including New York, Los Angeles, Seattle and Chicago. The most recent update showed that the index expanded 6.1% to 203 in August, breaking the previous all-time high of 198 from July of 2007. Take a look below.

SPCS20 Index Level Since July 2007

Looking forward, I am expecting another record year. Not only will interest rates remain relatively low, but I see no short-term solution to historically low housing inventories.

Top 5 Safest Stocks To Buy For 2019: Microvision Inc.(MVIS)

Advisors’ Opinion:

  • [By Max Byerly]

    IMPINJ (NASDAQ: PI) and MicroVision (NASDAQ:MVIS) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Microvision (MVIS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Microvision (MVIS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: Potlatch Corporation(PCH)

Advisors’ Opinion:

  • [By Logan Wallace]

    Itau Unibanco Holding S.A. bought a new position in Potlatchdeltic Corp (NASDAQ:PCH) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,644 shares of the real estate investment trust’s stock, valued at approximately $236,000.

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America bought a new position in PotlatchDeltic (NASDAQ:PCH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 78,505 shares of the real estate investment trust’s stock, valued at approximately $4,086,000. Teachers Insurance & Annuity Association of America owned approximately 0.19% of PotlatchDeltic at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on PotlatchDeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Potlatchdeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: H&R Block, Inc.(HRB)

Advisors’ Opinion:

  • [By Chris Lange]

    H&R Block, Inc. (NYSE: HRB) released fiscal fourth quarter financial results after markets closed Tuesday. The company reported $5.43 in earnings per share (EPS) and $2.39 billion in revenue compared with consensus estimates that called for $5.27 in EPS and $2.34 billion in revenue. The same period last year had $3.76 in EPS and $2.33 billion in revenue.

  • [By Paul Ausick]

    H&R Block Inc. (NYSE: HRB) traded down about 1.2% Tuesday and posted a new 52-week low of $23.28 after closing Monday at $23.55. The stock’s 52-week high is $31.80. Volume totaled about 3.1 million, about a third higher than the daily average of around  3.2 million. The company had no specific news. Shares have turned around and are headed for a gain of about 1.4% at the closing bell.

  • [By Joseph Griffin]

    TheStreet upgraded shares of H & R Block (NYSE:HRB) from a c+ rating to a b rating in a report released on Tuesday.

    Other equities research analysts have also issued research reports about the company. Barrington Research lowered their price objective on H & R Block from $32.00 to $27.00 and set an outperform rating for the company in a research note on Thursday. ValuEngine downgraded H & R Block from a sell rating to a strong sell rating in a report on Wednesday. Morgan Stanley reaffirmed an equal weight rating and set a $28.00 target price (up previously from $27.00) on shares of H & R Block in a report on Wednesday, March 7th. BMO Capital Markets reduced their target price on H & R Block from $29.00 to $25.00 and set a market perform rating on the stock in a report on Wednesday. Finally, Zacks Investment Research downgraded H & R Block from a strong-buy rating to a hold rating in a report on Tuesday, March 27th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. H & R Block presently has a consensus rating of Hold and a consensus price target of $26.21.

  • [By Billy Duberstein]

    Nationwide is also the second non-bank partner that has chosen to work with Bank of the Internet. The other is H&R Block (NYSE:HRB), which sold deposits to Bank of the Internet in 2015 and still works closely with BOFI on Refund Advance Loans. In fact, BOFI management also announced a renewal of its agreement with H&R Block on the recent call.

Top 5 Safest Stocks To Buy For 2019: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Wildhorse Resource Development Corp (NYSE:WRD) shares dropped 5.3% on Monday . The stock traded as low as $18.40 and last traded at $18.66. Approximately 1,428,160 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 1,115,212 shares. The stock had previously closed at $19.71.

  • [By Logan Wallace]

    Wildhorse Resource Development Corp (NYSE:WRD) – Equities research analysts at Capital One Financial lowered their FY2018 earnings per share estimates for Wildhorse Resource Development in a research note issued to investors on Monday, August 20th. Capital One Financial analyst B. Velie now forecasts that the oil and natural gas company will post earnings of $1.59 per share for the year, down from their previous estimate of $1.87. Capital One Financial also issued estimates for Wildhorse Resource Development’s Q4 2018 earnings at $0.39 EPS and FY2019 earnings at $2.07 EPS.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on WildHorse Resource Development (WRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: Keryx Biopharmaceuticals, Inc.(KERX)

Advisors’ Opinion:

  • [By Shane Hupp]

    Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 174.39% from the stock’s current price.

  • [By Logan Wallace]

    Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned an average rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

  • [By Ethan Ryder]

    Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.

  • [By Maxx Chatsko]

    Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) dropped nearly 20% last month, according to data from S&P Global Market Intelligence. The pharma company announced second-quarter and first-half 2018 results that included disappointing sales revenue for its only drug, Auryxia. As a result, sales lagged behind consensus estimates despite delivering strong year-over-year growth.

  • [By Stephan Byrd]

    Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have received a consensus rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

Leave a Reply

Your email address will not be published. Required fields are marked *